Form 4: Apellis CTO Granted 45,220 Restricted Stock Units

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, was granted 45,220 Restricted Stock Units vesting over four years.

Summary

• Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 45,220 Restricted Stock Units (RSUs).
• The grant date for these RSUs is January 28, 2026.
• The RSUs will vest 25% annually over a four-year period from the grant date, subject to continued service with the company.
• Following this transaction, Nur Nicholson beneficially owns 116,338 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retention and aligning management interests with long-term shareholder value, without indicating any immediate operational or financial shifts.

Positives

• The RSU grant serves as a long-term incentive for the Chief Technical Officer, aligning their interests with shareholder value creation.
• The four-year vesting schedule promotes executive retention and stability within the company's leadership.
• Equity-based compensation is a standard practice for attracting and retaining key talent in the pharmaceutical industry.

Negatives

• The grant of Restricted Stock Units, upon vesting, will result in a minor dilutive effect on existing shareholders as new shares are issued.
• There is no immediate cash transaction or direct purchase of shares by the executive, which might be seen as less of a direct vote of confidence compared to open market purchases.

Risks

• Future dilution of existing shareholders' ownership percentage as the granted Restricted Stock Units vest and convert into common stock.
• The value of the RSU award is subject to the future performance of Apellis Pharmaceuticals' stock price, introducing market risk for the recipient.

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units with a multi-year vesting schedule is a common and effective executive compensation strategy in the biotechnology and pharmaceutical sectors. This approach aims to align executive incentives with long-term company performance and shareholder value, while also serving as a retention mechanism for key leadership.

Comparison to Industry Standards

• RSU grants are a prevalent form of equity compensation across the technology and pharmaceutical industries, often preferred over stock options due to their inherent value even if the stock price does not significantly increase.
• A four-year vesting schedule, with annual increments, is standard for executive equity awards, comparable to practices at companies like Pfizer, Moderna, or Biogen, which use similar structures to incentivize long-term commitment and performance.
• The grant size of 45,220 RSUs for a Chief Technical Officer at a company like Apellis is within the typical range for senior executives, reflecting their strategic importance and contribution to product development and innovation.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs, but also benefit from executive retention and alignment of interests.
• Employees: May signal stability in leadership and a commitment to long-term incentives for key personnel.

Next Steps

• The 45,220 Restricted Stock Units will vest 25% annually over four years, subject to Nur Nicholson's continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (an RSU grant) and does not provide new information that would fundamentally alter the investment thesis for Apellis Pharmaceuticals. It reinforces executive retention but offers no immediate catalysts for significant price movement, thus a 'hold' recommendation is appropriate.

Keywords

Apellis Pharmaceuticals, APLS, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Nur Nicholson, Chief Technical Officer, Equity Grant, Form 4